Give Kids a Chance
A RACE AGAINST BLINDNESS

![]()

Millions of children worldwide are at risk of irreversible vision loss. This alarming trend is fueled by a lack of access to necessary treatments. Early intervention is crucial to prevent long-term developmental impacts and ensure every child can thrive.

Vision loss profoundly affects children's development and education, limiting their ability to engage and thrive in daily life and learning environments.
Long drug development times delay access to critical treatments for children, prolonging their suffering and increasing the risk of permanent vision loss.
The high costs associated with research and development create significant barriers, discouraging companies from pursuing treatments for rare pediatric diseases.
Regulatory hurdles slow down clinical trials, leading to additional delays in bringing innovative therapies to market for children in need.
The Priority Review Voucher (PRV) program incentivizes pharmaceutical companies to develop drugs for rare pediatric diseases through accelerated review processes.
PRVs allow faster regulatory review, helping to bring essential treatments to market more quickly and address urgent health needs in children.
These vouchers are awarded specifically for rare pediatric disease drug approvals, encouraging innovation and investment in areas with significant unmet medical needs.
Priority Review Vouchers can be sold or utilized to expedite the review process, significantly enhancing access to crucial treatments for children.
A recent case highlights the positive impact of Priority Review Vouchers, showcasing a child's journey towards enhanced vision and brighter opportunities.




Speeds up treatment access for vulnerable children.
Encourages funding for pediatric vision research initiatives.
Improves health results and quality of life for children.
Advocating for policies that promote Priority Review Vouchers is essential for ensuring faster treatments and brighter futures for children at risk.